XETRA - Delayed Quote EUR

Valneva SE (AYJ.DE)

Compare
1.8570 -0.0080 (-0.43%)
As of 1:17:26 PM GMT+1. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
158,535.0000
153,712.0000
361,303.0000
348,085.0000
110,321.0000
Cost of Revenue
97,371.0000
100,875.0000
324,441.0000
187,920.0000
54,302.0000
Gross Profit
61,164.0000
52,837.0000
36,862.0000
160,165.0000
56,019.0000
Operating Expense
142,713.0000
134,949.0000
150,236.0000
221,514.0000
111,140.0000
Operating Income
-81,549.0000
-82,112.0000
-113,374.0000
-61,349.0000
-55,121.0000
Net Non Operating Interest Income Expense
-26,759.0000
-22,115.0000
-18,794.0000
-16,714.0000
-10,620.0000
Other Income Expense
100,917.0000
5,598.0000
-12,648.0000
8,083.0000
437.0000
Pretax Income
-7,393.0000
-98,629.0000
-144,815.0000
-69,979.0000
-65,302.0000
Tax Provision
25.0000
2,800.0000
-1,536.0000
3,446.0000
-909.0000
Net Income Common Stockholders
-7,418.0000
-101,429.0000
-143,279.0000
-73,425.0000
-64,393.0000
Diluted NI Available to Com Stockholders
-7,418.0000
-101,429.0000
-143,279.0000
-73,425.0000
-64,393.0000
Basic EPS
-0.05
-0.73
-1.24
-0.75
-0.71
Diluted EPS
-0.06
-0.73
-1.24
-0.75
-0.71
Basic Average Shares
137,801.2140
138,943.8360
115,547.5810
97,619.3200
90,757.1730
Diluted Average Shares
143,864.9400
138,943.8360
115,547.5810
97,619.3200
90,757.1730
Total Operating Income as Reported
9,307.0000
-82,087.0000
-113,443.0000
-61,390.0000
-55,120.0000
Total Expenses
240,084.0000
235,824.0000
474,677.0000
409,434.0000
165,442.0000
Net Income from Continuing & Discontinued Operation
-7,418.0000
-101,429.0000
-143,279.0000
-73,425.0000
-64,393.0000
Normalized Income
-14,981.0000
-105,627.5000
-130,756.2482
-79,369.6800
-64,955.0656
Interest Income
1,802.0000
1,210.0000
260.0000
249.0000
119.0000
Interest Expense
28,561.0000
23,325.0000
19,054.0000
16,963.0000
10,739.0000
Net Interest Income
-26,759.0000
-22,115.0000
-18,794.0000
-16,714.0000
-10,620.0000
EBIT
21,168.0000
-75,304.0000
-125,761.0000
-53,016.0000
-54,563.0000
EBITDA
21,168.0000
-57,720.0000
-104,725.0000
-38,735.0000
-44,764.0000
Reconciled Cost of Revenue
97,371.0000
100,875.0000
324,441.0000
187,920.0000
54,302.0000
Reconciled Depreciation
--
17,584.0000
21,036.0000
14,281.0000
9,799.0000
Net Income from Continuing Operation Net Minority Interest
-7,418.0000
-101,429.0000
-143,279.0000
-73,425.0000
-64,393.0000
Total Unusual Items Excluding Goodwill
10,084.0000
5,598.0000
-12,657.0000
8,088.0000
570.0000
Total Unusual Items
10,084.0000
5,598.0000
-12,657.0000
8,088.0000
570.0000
Normalized EBITDA
11,084.0000
-63,318.0000
-92,068.0000
-46,823.0000
-45,334.0000
Tax Rate for Calcs
0.0003
0.0003
0.0000
0.0003
0.0000
Tax Effect of Unusual Items
2,521.0000
1,399.5000
-134.2482
2,143.3200
7.9344
12/31/2020 - 5/7/2010

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BIO.DE Biotest Aktiengesellschaft
41.40
0.00%
 
BIO3.DE Biotest Aktiengesellschaft
26.80
0.00%
 
9VC.DE Atai Life Sciences N.V.
1.4070
0.00%
 
T5O0.DE bioXXmed AG
1.4850
0.00%
 
88Q.DE 4basebio PLC
14.60
0.00%
 
7V0.DE Darwin AG
27.40
+0.74%
 
VX1.DE Vertex Pharmaceuticals Incorporated
441.35
0.00%
 
PSH.DE Sernova Corp.
0.1527
-7.34%
 
NP5.DE Newron Pharmaceuticals S.p.A.
8.01
-2.55%
 
HPHA.DE Heidelberg Pharma AG
2.4800
0.00%